• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13D/A filed by Cingulate Inc.

    7/16/24 7:14:57 PM ET
    $CING
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $CING alert in real time by email
    SC 13D/A 1 formsc13da.htm

     

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 15)*

     

    Cingulate Inc.
    (Name of Issuer)
     
    COMMON STOCK, PAR VALUE $0.0001 PER SHARE
    (Title of Class of Securities)
     
    17248W204
    (CUSIP Number)
     

    Shane J. Schaffer

    Chief Executive Officer

    1901 W. 47th Place

    Kansas City, KS 66205

    Telephone Number (913) 942-2300

    (Name, Address and Telephone Number of Person

    Authorized to Receive Notices and Communications)

     
    July 12, 2024
    (Date of Event Which Requires Filing of this Statement)

     

    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of ss.240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box ☐.

     

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

     

     

     

     
     

     

    CUSIP No. 17248W204  
    1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only):  
      Peter J. Werth  
    2. Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐
    3. SEC Use Only  
    4. Source of Funds (See Instructions): PF  
    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):  
      ☐  
    6. Citizenship or Place of Organization: United States  
      Number of 7. Sole Voting Power: 2,518*
      Shares Beneficially 8. Shared Voting Power: 1,176,340*
      Owned by    
      Each Reporting 9. Sole Dispositive Power: 2,518*
      Person With 10. Shared Dispositive Power: 1,176,340*
    11. Aggregate Amount Beneficially Owned by Each Reporting Person:
      1,178,858*
    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):
      ☐
    13. Percent of Class Represented by Amount in Row (11): 11.27%*
    14. Type of Reporting Person (See Instructions): IN

     

    *As of the date hereof, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Peter J. Werth (“Mr. Werth”) may be deemed to beneficially own an aggregate of 1,178,858 shares of common stock, par value $0.0001 per share (the “Common Stock”), of Cingulate Inc. (the “Issuer”) consisting of (i) 1,093 shares of Common Stock and stock options to purchase 1,425 shares of Common Stock held directly by Mr. Werth and (ii) 1,175,925 shares of Common Stock and warrants to purchase up to 415 shares of Common Stock held directly by Werth Family Investment Associates LLC (“Werth Associates”) where Mr. Werth serves as Manager. Excludes 18,975 shares of Common Stock underlying unvested stock options held directly by Mr. Werth.

     

    The foregoing reported beneficial ownership percentage is based upon 10,457,921 shares of Common Stock issued and outstanding as of July 12, 2024. The number of shares of Common Stock issued and outstanding reflects the 1-for-20 reverse stock split of the Issuer’s issued and outstanding shares of Common Stock, which became effective on November 30, 2023.

     

     
     

     

    CUSIP No. 17248W204  
    1. Names of Reporting Persons. I.R.S. Identification Nos. of above persons (entities only):  
      Werth Family Investment Associates LLC  
    2. Check the Appropriate Box if a Member of a Group (a) ☐
        (b) ☐
    3. SEC Use Only  
    4. Source of Funds (See Instructions): WC  
    5. Check if Disclosure of Legal Proceedings Is Required Pursuant to Items 2(d) or 2(e):  
      ☐  
    6. Citizenship or Place of Organization: Connecticut  
      Number of 7. Sole Voting Power: 0
      Shares Beneficially 8. Shared Voting Power: 1,176,340**
      Owned by    
      Each Reporting 9. Sole Dispositive Power: 0
      Person With 10. Shared Dispositive Power: 1,176,340**
    11. Aggregate Amount Beneficially Owned by Each Reporting Person:
      1,176,340**
    12. Check if the Aggregate Amount in Row (11) Excludes Certain Shares (See Instructions):
      ☐
    13. Percent of Class Represented by Amount in Row (11): 11.25%**
    14. Type of Reporting Person (See Instructions): OO

     

    ** As of the date hereof, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Werth Family Investment Associates LLC (“Werth Associates”) may be deemed to beneficially own 1,176,340 shares of common stock, par value $0.0001 per share (the “Common Stock”), of Cingulate Inc. (the “Issuer”), consisting of 1,175,925 shares of Common Stock and warrants to purchase up to 415 shares of Common Stock.

     

    The foregoing reported beneficial ownership percentage is based upon 10,457,921 shares of Common Stock issued and outstanding as of July 12, 2024. The number of shares of Common Stock issued and outstanding reflects the 1-for-20 reverse stock split of the Issuer’s issued and outstanding shares of Common Stock, which became effective on November 30, 2023.

     

     
     

     

    Explanatory Note

     

    This Amendment No. 15 (this “Amendment”) amends and supplements the Schedule 13D filed on behalf of the Reporting Persons with the Securities and Exchange Commission on December 20, 2021, as amended on December 23, 2022, July 25, 2023, August 14, 2023, September 18, 2023, November 8, 2023, January 4, 2024, January 29, 2024, February 9, 2024, February 28, 2024, April 12, 2024, May 28, 2024, June 7, 2024, June 27, 2024 and July 2, 2024 (the “Schedule 13D”). Except as specifically provided herein, this Amendment does not modify or amend any of the information previously reported in the Schedule 13D. Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to such terms in the Schedule 13D. Information given in response to each item shall be deemed incorporated by reference in all other items, as applicable.

     

    The number of shares of Common Stock issued and outstanding reflects the 1-for-20 reverse stock split of the Issuer’s issued and outstanding shares of Common Stock, which became effective on November 30, 2023.

     

     
     

     

    Item 5. Interest in Securities of the Issuer.

     

    The information contained in rows 7, 8, 9, 10, 11 and 13 of the cover page of this Schedule 13D and the information set forth in or incorporated by reference in Item 2, Item 3 and Item 6 of this Schedule 13D is hereby incorporated by reference in its entirety into this Item 5.

     

    The aggregate percentage of Common Stock reported owned by the Reporting Persons is based upon 10,457,921 shares of Common Stock outstanding, which is the total number of shares of Common Stock outstanding as of July 12, 2024. The number of shares of Common Stock issued and outstanding reflects the 1-for-20 reverse stock split of the Issuer’s issued and outstanding shares of Common Stock, which became effective on November 30, 2023.

     

    As of the date hereof, for purposes of Rule 13d-3 under the Securities Exchange Act of 1934, as amended, Mr. Werth may be deemed to beneficially own 1,178,858 shares of Common Stock of the Issuer, consisting of (i) 1,093 shares of Common Stock and stock options to purchase 1,425 shares of Common Stock held directly by Mr. Werth and (ii) 1,175,925 shares of Common Stock and warrants to purchase up to 415 shares of Common Stock held directly by Werth Associates.

     

    Except as described herein, during the past sixty (60) days on or prior to the date hereof, there were no other purchases or sales of shares of Common Stock, or securities convertible into or exchangeable for shares of Common Stock, by the Reporting Persons or any person or entity for which the Reporting Persons possess voting or dispositive control over the securities thereof.

     

     
     

     

    Signature

     

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

      July 16, 2024
       
      By: /s/ Peter J. Werth*
        Peter J. Werth

     

      WERTH FAMILY INVESTMENT ASSOCIATES LLC
         
      By: Peter J. Werth, its Manager

     

      By: /s/ Peter J. Werth
      Name: Peter J. Werth
      Title: Manager

     

    * This reporting person disclaims beneficial ownership of these reported securities except to the extent of its pecuniary interest therein, and this report shall not be deemed an admission that any such person is the beneficial owner of these securities for purposes of Section 16 of the U.S. Securities Exchange Act of 1934, as amended, or for any other purpose.

     

    Attention: Intentional misstatements or omissions of fact constitute
    Federal criminal violations (see 18 U.S.C. 1001).

     

     

     

    Get the next $CING alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $CING

    DatePrice TargetRatingAnalyst
    1/10/2025$12.00Buy
    ROTH MKM
    12/22/2023Buy → Hold
    Laidlaw
    1/20/2022$8.50Buy
    Laidlaw & Co.
    1/11/2022$9.00Buy
    Aegis Capital
    More analyst ratings

    $CING
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • ROTH MKM initiated coverage on Cingulate with a new price target

      ROTH MKM initiated coverage of Cingulate with a rating of Buy and set a new price target of $12.00

      1/10/25 7:39:52 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cingulate downgraded by Laidlaw

      Laidlaw downgraded Cingulate from Buy to Hold

      12/22/23 7:22:08 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Laidlaw & Co. initiated coverage on Cingulate with a new price target

      Laidlaw & Co. initiated coverage of Cingulate with a rating of Buy and set a new price target of $8.50

      1/20/22 9:15:46 AM ET
      $CING
      Biotechnology: Pharmaceutical Preparations
      Health Care